Trial Profile
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 06 Oct 2009 Sponsor and lead trial centre (Schering-Plough) added as reported by ClinicalTrials.gov.
- 14 Mar 2007 New trial record.